论文部分内容阅读
Aim To perform a meta-analysis of the efficacy and safety of (bortezomib plus lenalidomide/thalidomide) vs (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma.Methods We searched electronic and printed sources for relevant articles published.Inclusion criteria was as follows:randomized controlled trials (RCT) of (bortezomib plus lenalidomide/thalidomide) vs (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma.Two reviewers independently assessed potentially eligible studies and extracted relevant data.Results We retrieved 5 RCT studies including a total of 1200 patients.